AmpliPhi’s product development pathway

  • Development
  • Preclinical
  • Phase 1/2
  • Phase 3

AmpliPhi Biosciences is the first company to demonstrate the clinical efficacy of phage technology in a controlled, regulated, human clinical trial. The Company’s leading bacteriophage therapeutic programs target areas of significant unmet clinical need, and its proprietary technology has additional applications for the treatment of a broad range of serious infections.

Scroll over bars to the left for information.